

-Press release published by Pharmanutra S.p.A on behalf of Andrea Lacorte, Roberto Lacorte, Beda S.r.l., Gianni Lazzarini, Vertigo Partners S.r.l. and IPO Challenger 1 S.p.A.

PRESS RELEASE

THE MAJORITY SHAREHOLDERS OF PHARMANUTRA S.p.A INCREASE THEIR SHARE HOLDING IN THE COMPANY THROUGH A TRANSACTION IN LINE WITH THE LOCK-UP AGREEMENT

Pisa, 16th April 2019 – The major shareholders of Pharmanutra S.p.A, leading pharmaceutical firm in the iron-based nutritional supplements field (“PHN” or the “**Company**”) give notification that transactions have been completed on today’s date by Andrea Lacorte, Roberto Lacorte and Beda S.r.l. of a PHN share package, representing 4.54% of the overall share capital, previously owned by Gianni Lazzarini. The shares acquired are subject to a *lock-up agreement*, in continuity with the commitments undertaken by the founders of PHN with IPO Challenger 1 S.p.A., having also consulted Nomad in the context of the operation for the admission of financial instruments of PHN on AIM Italia.

On today's date the presence of institutional investors in the PHN capital increased through the sale of PHN shares (overall equal to 3.51% of the capital) by Gianni Lazzarini and by Vertigo Partners S.r.l through *reverse book building* operations.

The above transactions confirm the PHN major shareholders’ belief in the potential for continued growth and development for the Company, the group and it’s *management team*, and together with the close attention to the financial market, are part of the process aimed at creating the conditions for the transference of PHN shares to the STAR segment of the Italian Stock Exchange.

As a result of the aforementioned acquisitions in which Vertigo Partners S.r.l has relinquished all its shares held in PHN, Gianni Lazzarini has maintained a minority shareholding in PHN, while the major shareholders and founders of PHN, Andrea Lacorte, Roberto Lacorte and Beda S.r.l have increased their shares in PHN and respectively own a stake of 32.21%, 23.95% and 11.31% of the share capital in question.

The major shareholders, Andrea Lacorte – President of Pharmanutra S.p.A, Roberto Lacorte – Vice President of Pharmanutra S.p.A, Carlo Volpi – Managing director of Pharmanutra S.p.A, commented: *“This operation is proof of the conviction that we partners – directly and personally involved in the creation and development of the business – place in the Company and in the room for growth that will take shape in the coming years. We are proud to share the continued growth of our company with an ever-increasing number of national and international investors of the highest standing, among them the Norwegian sovereign fund, who we recognise in the assembly sessions and organised encounters”.*

PharmaNutra S.p.A.

Founded and guided by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra was established in 2003 and develops unique nutraceutical supplements and innovative nutritional devices, handling the entire production process, from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by numerous clinical studies, 91 of which have been published the involvement of over 6,000 patients. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents for sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com